Abstract: The invention relates to a method for producing pharmaceutical forms or preliminary stages thereof by means of extrusion. The pharmaceutical form has a matrix which the active agent is contained essentially, and whose essential characteristics are determined by the extrusion process and which comprises a polysaccharide and/or derivative thereof and/or a complex thereof and/or any mixture of the aforementioned substances with other substances and/or saccharides and/or derivatives thereof as an essential constituent, and at least one pharmaceutically active substance.

Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.

Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which upon administration quickly release an effective portion of the opioid contained therein such that there is an initially more rapid opioid release so that the minimum effective analgesic concentration of the opioid can be more quickly achieved. In the method, the formulations are designed to provide a relatively large peak to trough concentration of the opioid, rather than a flattened serum concentration curve.

Abstract: A stabilized solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic polymer is obtained by overcoating a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, with an aqueous dispersion of the plasticized hydrophobic polymer and then curing the coated substrate at a temperature above the glass transition temperature of the plasticized hydrophobic polymer, until a curing endpoint is reached at which the coated substrate provides a stabilized dissolution of the active agent which is unchanged after exposure to accelerated storage conditions, the endpoint being determined by comparing the dissolution profile of the formulation immediately after curing to the dissolution profile of the formulation after exposure to accelerated storage conditions of at least one month at

Abstract: Stable aqueous dispersions of zein which may be used as controlled release coatings of pharmaceutical, animal, health, or food products in an inorganic solvent-free environment are disclosed, as well as methods for preparing the same.

Abstract: Aqueous dispersions of zein which may be used in the coating of pharmaceutical, animal, health, or food products in an inorganic solvent-free environment are disclosed, as well as methods for preparing the same.

Abstract: A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of an acrylic polymer is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of the plasticized acrylic polymer and then curing the coated substrate at a temperature above the glass transition temperature of the plasticized acrylic polymer, until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Abstract: A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of oxycodone or a salt thereof in a matrix wherein the dissolution rate in vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. is between 12.5% and 42.5% (by weight) oxycodone released after 1 hour, between 25% and 55% (by weight) oxycodone released after 2 hours, between 45% and 75% (by weight) oxycodone released after 4 hours and between 55% and 85% (by weight) oxycodone released after 6 hours, the in vitro release rate being independent of pH between pH 1.6 and 7.2 and chosen such that the peak plasma level of oxycodone obtained in vivo occurs between 2 and 4 hours after administration of the dosage form.

Abstract: The stability of compositions of choline salicylate-metal salicylate-carboxymethylcellulose is improved by the incorporation therein of microcrystalline cellulose. The microcrystalline cellulose is linked to the remainder of the composition by liquid bridges and is preferably present in an amount of about 2.5-25% by weight. The microcrystalline cellulose enhances the stability of the composition and thereby enhances solid dosage forms thereof such as tablets, capsules, suppositories and granules.

Abstract: The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.

Abstract: Swab apparatus for use in topical application of treatment materials comprise a swab, a flexible-walled container having an interior in which a quantity of treatment material is situated, and a coupling tube having a forward end portion to which the swab is connected and a rearward end portion coupled to the container, for placing the swab and the treatment material within the container into fluid communication with each other.

Abstract: Povidone-Iodine (PVP-I) solutions stable according to U.S.P. standards and a method for preparing the same are disclosed. The PVP-I solution includes a microbicidal effective amount of available iodine and an alkalinizing agent in an effective amount to maintain the stability of the solution for a desired shelf-life of the solution when said solution is stored in a substantially nonpermeable container, the solution being non-buffered. In preferred embodiments, the iodophor solution is a microbicidal PVP-I solution for ophthalmic use.

Abstract: The invention relates to a lousicidal shampoo composition of phenothrin as lousicidal agent distributed in a shampoo base of water and one or more surface active agents, the shampoo containing as antimicrobial preservative 2-bromo-2-nitropropane-1,3-diol alone or in combination with 2,4-dichlorobenzyl alcohol.

Abstract: A controlled release, solid, oral dosage form containing a 3-alkylxanthine, preferably theophylline, at least one hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25.degree. and 90.degree. C. and between 3% and 10% (by weight) water.Preferably the dosage form is a tablet and the water content is between 4% and 9% (by weight). The amount of water present in the dosage form determines the rate of release of the 3-alkylxanthine.

Abstract: An ion exchange resin composition which is readily dispersible in water is provided. This resin composition comprises a granulated ion exchange resin, a pharmacologically active ingredient bound thereto with a sugar or sugar alcohol, and a sufficient amount of water, alcohol or aqueous alcohol to facilitate granulation. The invention further comprises a method for the preparation of such ion exchange resin composition.

Abstract: Novel substituted dibenzofuran compounds are disclosed. The compounds exhibit activity in antagonizing the effects of leukotriene B.sub.4 (LTB.sub.4). Pharmaceutical compositions containing the novel compounds and methods of treatment employing the same are also described.

Abstract: A 6-thioxanthine of formula I or a pharmaceutically acceptable salt thereof ##STR1## wherein R.sub.3 is a C.sub.2 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group and R.sub.8 is a C.sub.1 to C.sub.6 alkyl group, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group provided that when R.sub.3 is an ethyl, n-propyl or n-butyl group, R.sub.8 is a C.sub.3 to C.sub.6 alkyl, a C.sub.3 to C.sub.7 cycloalkyl group or a C.sub.4 to C.sub.8 cycloalkylalkyl group.These 3,8-disubstituted-6-thioxanthines have enhanced bronchodilator activity.

Abstract: Minimizing the leaching of iodine through packaging containing organic iodophor solution, by introducing into the packaging an amount of additional iodide which minimizes leaching of the iodine through the packaging and stabilizes the iodophor solution therein. The iodophor is preferably polyvinylpyrrolidone iodine.

Abstract: Novel substituted isoquinoline compounds are disclosed together with novel 2-phenylethylamides useful as precursors or intermediates for the production of the isoquinolines. The substituted isoquinolines exhibit activity in antagonizing the effects of platelet activating factor (PAF).